Phathom Pharmaceuticals, Inc.

NasdaqGS:PHAT Stock Report

Market Cap: US$572.3m

Phathom Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGS:PHAT Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
13 Dec 24BuyUS$99,084Frank KarbeIndividual12,500US$7.93
13 Dec 24BuyUS$81,248Asit ParikhIndividual10,000US$8.12
15 Jul 24SellUS$396,699Terrie CurranIndividual33,848US$11.72
15 Jul 24SellUS$50,689Molly HendersonIndividual4,325US$11.72
15 Jul 24SellUS$127,760Azmi NabulsiIndividual10,901US$11.72
09 Apr 24SellUS$4,029,196Takeda Pharmaceutical Company LimitedCompany362,737US$11.94
08 Apr 24SellUS$38,129Molly HendersonIndividual3,435US$11.10
28 Mar 24SellUS$6,435,841Takeda Pharmaceutical Company LimitedCompany602,366US$10.89
22 Mar 24SellUS$153,513Terrie CurranIndividual16,851US$9.11
24 Jan 24SellUS$29,999,994Takeda Pharmaceutical Company LimitedCompany3,703,703US$8.10
19 Jan 24SellUS$48,900Molly HendersonIndividual6,307US$7.75

Insider Trading Volume

Insider Buying: PHAT insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of PHAT?
Owner TypeNumber of SharesOwnership Percentage
Private Companies18,8490.0233%
Individual Insiders2,498,5333.08%
Public Companies2,790,4803.44%
VC/PE Firms21,070,65926%
Institutions54,671,70467.5%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 19.4%.

Top Shareholders

Top 25 shareholders own 96.95% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
14.8%
Frazier Life Sciences Management, LP
10,109,279US$84.6m0%3.2%
10.9%
Medicxi Ventures (UK) LLP
7,464,572US$62.5m0%12.12%
10.2%
Jennison Associates LLC
6,993,422US$58.5m19.2%0.03%
5.59%
Invesco Ltd.
3,820,003US$32.0m21.6%0.01%
5.11%
Abingworth LLP
3,496,808US$29.3m0%26.61%
4.57%
BlackRock, Inc.
3,122,570US$26.1m6.7%no data
4.08%
Takeda Pharmaceutical Company Limited
2,790,480US$23.4m0%no data
3.94%
The Vanguard Group, Inc.
2,696,323US$22.6m21.9%no data
3.78%
Ensign Peak Advisors, Inc.
2,581,388US$21.6m15%0.03%
3.76%
Woodline Partners LP
2,573,412US$21.5m227%0.17%
2.87%
New Enterprise Associates, Inc.
1,960,169US$16.4m0%0.74%
2.64%
Avidity Partners Management, L.P.
1,804,493US$15.1m11.4%0.8%
2.49%
Portolan Capital Management, LLC
1,699,918US$14.2m50.4%0.89%
2.37%
Gilder Gagnon Howe & Co. LLC
1,622,883US$13.6m10.2%0.13%
2.2%
Checkpoint Capital, LLC, Asset Management Arm
1,504,307US$12.6m71.9%6.17%
2.12%
OrbiMed Advisors LLC
1,449,073US$12.1m0%0.16%
2.05%
Federated Hermes, Inc.
1,403,638US$11.7m0%0.03%
1.91%
FMR LLC
1,304,114US$10.9m49,000%no data
1.83%
Decheng Capital LLC
1,250,000US$10.5m47.1%2.31%
1.82%
Strategic Advisers LLC
1,243,191US$10.4m28.9%no data
1.79%
David Socks
1,220,756US$10.2m0%no data
1.65%
GW&K Investment Management, LLC
1,126,083US$9.4m87.5%0.07%
1.64%
Catalys Pacific
1,122,572US$9.4m55.5%7.89%
1.48%
683 Capital Management, LLC
1,010,000US$8.5m-27.9%0.79%
1.35%
State Street Global Advisors, Inc.
922,788US$7.7m17.5%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/18 22:50
End of Day Share Price 2024/12/18 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Phathom Pharmaceuticals, Inc. is covered by 11 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullBMO Capital Markets Equity Research
Chase KnickerbockerCraig-Hallum Capital Group LLC
Umer RaffatEvercore ISI